COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

47 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-15

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amyotrophic Lateral Sclerosis and the Innate Immune System

NCT02869048

Amyotrophic Lateral Sclerosis Neurodegenerative Disease Motor Neuron Disease

RECRUITING

Amyotrophic Lateral Sclerosis Registry

NCT05892822

Amyotrophic Lateral Sclerosis

UNKNOWN

ALS Research Collaborative

NCT06885918

Amyotrophic Lateral Sclerosis ALS (Amyotrophic Lateral Sclerosis) ALS With Frontotemporal Dementia (ALS/FTD) +2 more

RECRUITING

A Registered Cohort Study on Amyotrophic Lateral Sclerosis

NCT04008329

Amyotrophic Lateral Sclerosis

RECRUITING

Methodology Study of Novel Outcome Measures to Assess Progression of ALS

NCT02611674

Amyotrophic Lateral Sclerosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this registry is to assess the incidence and prevalence of COVID-19 in ALS patients, the effect of COVID-19 on ALS disease trajectory, and the impact, if any, of edaravone, riluzole and other concomitant medication used in ALS like Albuterol and dextromethorphan/quinidine (Nuedexta) on these parameters. COVID-19 incidence and prevalence in the ALS population will be assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Amyotrophic Lateral Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of ALS and
* A confirmed COVID-19 infection determined by:

1. positive SARS-CoV-2 viral RNA PCR test and/or
2. positive serology antibody testing for SARS-CoV-2